Uridine triacetate
Clinical data
Trade namesVistogard, Xuriden
Other namesvistonuridine
AHFS/Drugs.comMonograph
MedlinePlusa616020
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismPyrimidine catabolic pathway
Onset of actionTmax = 2–3 hours
Elimination half-life2–2.5 hours
ExcretionKidney
Identifiers
  • [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.021.710 Edit this at Wikidata
Chemical and physical data
FormulaC15H18N2O9
Molar mass370.314 g·mol−1
3D model (JSmol)
  • CC(=O)OCC1C(C(C(O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C
  • InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1
  • Key:AUFUWRKPQLGTGF-FMKGYKFTSA-N

Uridine triacetate (INN),[1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine[2] used:

Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.[9][10][11]

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. p. 92. Retrieved 12 March 2017.
  2. ^ "Uridine triacetate — DrugBank Page". 12 March 2017.
  3. ^ "Xuriden- uridine triacetate granule". DailyMed. 16 December 2019. Retrieved 20 October 2020.
  4. ^ "Vistogard- uridine triacetate granule". DailyMed. 15 November 2018. Retrieved 20 October 2020.
  5. ^ "BTG Announces FDA Approval of Vistogard (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine". BTG International Ltd. 11 December 2015. Retrieved 12 March 2017.
  6. ^ "Approved Drugs — Uridine Triacetate". U.S. Food and Drug Administration. Archived from the original on 3 March 2016. Retrieved 12 March 2017.
  7. ^ Cada DJ, Mbogu U, Bindler RJ, Baker DE (June 2016). "Uridine Triacetate". Hospital Pharmacy. 51 (6): 484–8. doi:10.1310/hpj5106-484. PMC 4911989. PMID 27354750.
  8. ^ Ison G, Beaver JA, McGuinn WD, Palmby TR, Dinin J, Charlab R, et al. (September 2016). "FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs". Clinical Cancer Research. 22 (18): 4545–4549. doi:10.1158/1078-0432.CCR-16-0638. PMID 27401247. S2CID 25746700.
  9. ^ "Xuriden (uridine triacetate) oral granules". U.S. Food and Drug Administration (FDA). 8 October 2015. Archived from the original on 8 December 2019. Retrieved 7 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  10. ^ "Drug Trials Snapshots: Xuriden". U.S. Food and Drug Administration (FDA). 4 September 2015. Archived from the original on 8 December 2019. Retrieved 8 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ^ "Previous Cumulative CY CDER BT Approvals" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 8 December 2019. Retrieved 7 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.

External links


Other alimentary tract and metabolism products (A16)
More
Categories